Lee L H, Jennings I, Luddington R, Baglin T
Department of Haematology, Addenbrooke's NHS Trust, Cambridge.
J Clin Pathol. 1994 Jul;47(7):631-4. doi: 10.1136/jcp.47.7.631.
To determine the prevalence of a biochemically detectable hypercoagulable state, defined in terms of increased thrombin or plasmin generation, in patients with phenotypically characterised thrombophilia.
Plasma concentrations of the prothrombin activation peptide F1.2 and fibrin degradation (FbDP) and fibrinogen degradation products (FgDP) were measured by enzyme immunoassay in 104 patients deficient in natural anticoagulants, and 35 unaffected relatives.
Increased concentrations of F1.2, FbDP, and FgDP were present in 18, 25, and 19 of 104 patients, respectively. There were no correlations between F1.2, FbDP, and FgDP concentrations, or between these parameters and concentrations of natural anticoagulants except for a negative correlation between protein C concentrations and FgDP (rho = -0.46, p = 0.009).
A biochemically detectable hypercoagulable state is present in some patients with asymptomatic thrombophilia. Markers of plasmin generation may be increased more frequently in thrombophilia than markers of thrombin generation. This finding should prompt the inclusion of markers of plasmin generation in prospective longitudinal cohort studies to determine the predictive value of a hypercoagulable state, defined by either excessive thrombin or plasmin generation, for the development of venous thromboembolism.
确定在具有表型特征的易栓症患者中,以凝血酶或纤溶酶生成增加来定义的生化可检测高凝状态的患病率。
采用酶免疫测定法,对104例缺乏天然抗凝剂的患者和35名未受影响的亲属测定凝血酶原激活肽F1.2、纤维蛋白降解产物(FbDP)和纤维蛋白原降解产物(FgDP)的血浆浓度。
104例患者中,F1.2、FbDP和FgDP浓度升高的分别有18例、25例和19例。F1.2、FbDP和FgDP浓度之间,以及这些参数与天然抗凝剂浓度之间均无相关性,但蛋白C浓度与FgDP之间呈负相关(rho = -0.46,p = 0.009)。
部分无症状易栓症患者存在生化可检测的高凝状态。易栓症患者中纤溶酶生成标志物可能比凝血酶生成标志物更频繁地升高。这一发现应促使在前瞻性纵向队列研究中纳入纤溶酶生成标志物,以确定由凝血酶或纤溶酶生成过多所定义的高凝状态对静脉血栓栓塞发生的预测价值。